Laura E Niklason has bought HUMA on 2 days since Aug 2021

Dr. Laura E. Niklason is a physician, researcher, and entrepreneur serving as President, CEO, and founder of Humacyte, Inc., a regenerative medicine company developing bioengineered human tissues( She holds the Nicholas M. Greene Professor of Anesthesiology and Biomedical Engineering at Yale University, where she has been faculty since 2006( Niklason co-founded Humacyte in 2004 with Drs. Shannon Dahl and Juliana Blum while at Duke University, where she was a faculty member from 1998 to 2005( She assumed the CEO and president role in November 2020 and led the company's transition to public markets in August 2021 through a SPAC merger, which raised $245 million and valued the company at approximately $1.1 billion(

Niklason's research focuses on regenerative strategies for cardiovascular and lung tissues, with her breakthrough invention being the human acellular vessel (HAV)—an off-the-shelf, universally implantable bioengineered tissue( The first U.S. human surgical implant of the HAV occurred in 2013 at Duke, and the technology subsequently received FDA fast track designation for vascular access in hemodialysis in 2014 and regenerative medicine advanced therapy designation in 2017( Her accomplishments include election to the National Academy of Inventors (2014), National Academy of Medicine (2015), and National Academy of Engineering (2020), as well as recognition by Time Magazine as one of the 50 best inventions of 2010 for her engineered lung technology( Niklason earned her PhD in Biophysics from the University of Chicago and her MD from the University of Michigan, completing residency training at Massachusetts General Hospital and postdoctoral training at MIT(

Written by Perplexity from public sources.